The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta‐analysis.

Note: the green color indicates higer sucra values with a greater probability ofbeing the more effective (c) or the safer (d) treatment and the red color indicates lower sucra values with a lower probability of being the best (c) or the safest treatment. gl When we analyzed safety outcomes, reduced toxicity was associated with increased SUCRA values. 7 Molica S, Giannarelli D, Montserrat E. Comparison between Venetoclax-based and Bruton tyrosine kinase inhibitor-based therapy as upfront treatment of chronic lymphocytic leukemia (CLL): a systematic review and network meta-analysis. To the Editor, The current shift in the treatment paradigm from chemoimmunotherapy to targeted agent (TA) therapy has rapidly changed the therapeutic landscape of chronic lymphocytic leukemia (CLL).[1] Current European and US guidelines recommend continuous first-generation or second-generation Bruton tyrosine kinase inhibitors (BTKis) and time-limited venetoclax-based therapy in the setting of previously untreated or relapsed-refractory CLL.[[2]] However, the lack of head-to-head randomized clinical trials, especially in the upfront setting, limits the potential of guidelines to address questions related to the choice of TA. Of note, adverse events lead to lower adherence to therapy, compromising the chosen treatment's clinical efficacy and need to be considered in treatment selection.[19] This study has some limitations. [Extracted from the article]